|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Pre-payment | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Capitalized patent costs, net | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Affiliated Entity | ||||||||||||||||||||
| Total accounts payable and accrued expenses | ||||||||||||||||||||
| Accounts payable affiliates | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Un-issued shares liability | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Short term loan | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total short term loan | ||||||||||||||||||||
| Loan from affiliates | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Affiliated Entity | ||||||||||||||||||||
| Total loan from affiliates | ||||||||||||||||||||
| Other short-term loans | ||||||||||||||||||||
| Derivative Liability | ||||||||||||||||||||
| Convertible notes payable, net of premium and discount | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred stock, $0.001 par value; 50,000,000 shares authorized, 43,283,991 issued and outstanding as at June 30, 2026, and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.001 par value; 400,000,000 shares authorized; 114,695,220 and 108,147,731 issued and outstanding as at June 30, 2026, and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital Common Stock | ||||||||||||||||||||
| Stock subscription | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Shares sold not issued | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
